keyword
MENU ▼
Read by QxMD icon Read
search

Pioglitazon

keyword
https://www.readbyqxmd.com/read/28229909/paradoxical-inhibition-of-glycolysis-by-pioglitazone-opposes-the-mitochondriopathy-caused-by-aif-deficiency
#1
Paule Bénit, Alice Pelhaître, Elise Saunier, Sylvie Bortoli, Assetou Coulibaly, Malgorzata Rak, Manuel Schiff, Guido Kroemer, Massimo Zeviani, Pierre Rustin
Mice with the hypomorphic AIF-Harlequin mutation exhibit a highly heterogeneous mitochondriopathy that mostly affects respiratory chain complex I, causing a cerebral pathology that resembles that found in patients with AIF loss-of-function mutations. Here we describe that the antidiabetic drug pioglitazone (PIO) can improve the phenotype of a mouse Harlequin (Hq) subgroup, presumably due to an inhibition of glycolysis that causes an increase in blood glucose levels. This glycolysis-inhibitory PIO effect was observed in cultured astrocytes from Hq mice, as well as in human skin fibroblasts from patients with AIF mutation...
February 16, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28219679/thiazolidinediones-abrogate-cervical-cancer-growth
#2
Beverly R Wuertz, Lindsay Darrah, Justin Wudel, Frank G Ondrey
Peroxisome proliferator-activated receptor gamma (PPAR γ) is activated by thiazolidinedione drugs (TZDs) and can promote anti-cancer properties. We used three TZDs (pioglitazone, rosiglitazone, and ciglitazone) to target cervical cancer cell lines and a nude mouse animal model. Each agent increased activation of PPAR γ, as judged by a luciferase reporter gene assay in three HPV-associated cell lines (CaSki, SiHa, and HeLa cells) while decreasing cellular proliferation in a dose-dependent manner. They also promoted Oil Red O accumulation in treated cell lines and upregulated the lipid differentiation marker adipsin...
February 17, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28219664/effect-of-pioglitazone-on-cardiometabolic-risk-in-patients-with-obstructive-sleep-apnea
#3
Alice Liu, Fahim Abbasi, Sun H Kim, Danit Ariel, Cindy Lamendola, James Cardell, Shiming Xu, Shailja Patel, Vanessa Tomasso, Hafasa Mojaddidi, Kaylene Grove, Philip S Tsao, Clete A Kushida, Gerald M Reaven
Prevalence of insulin resistance is increased in patients with obstructive sleep apnea (OSA). Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA. Patients (n = 30) were administered pioglitazone (45 mg/day) for 8 weeks, and measurements were made before and after intervention of insulin action (insulin-mediated glucose uptake by the insulin suppression test), C-reactive protein, lipid/lipoprotein profile, and gene expression profile of periumbilical subcutaneous fat tissue...
January 25, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28214603/the-impact-of-reduced-gastric-acid-secretion-on-dissolution-of-salts-of-weak-bases-in-the-fasted-upper-gastrointestinal-lumen-data-in-biorelevant-media-and-in-human-aspirates
#4
Chara Litou, Maria Vertzoni, Wei Xu, Filippos Kesisoglou, Christos Reppas
PURPOSE: To propose media for simulating the intragastric environment under reduced gastric acid secretion in the fasted state at three levels of simulation of the gastric environment and evaluate their usefulness in evaluating the intragastric dissolution of salts of weak bases. To evaluate the importance of bicarbonate buffer in biorelevant in vitro dissolution testing when using Level II biorelevant media simulating the environment in the fasted upper small intestine, regardless of gastric acid secretions...
February 15, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28213289/quercetin-and-pioglitazone-synergistically-reverse-endothelial-dysfunction-in-isolated-aorta-from-fructose-streptozotocin-f-stz-induced-diabetic-rats
#5
Thubasni Kunasegaran, Mohd Rais Mustafa, Francis I Achike, Dharmani Devi Murugan
Pioglitazone is an anti-diabetic drug with potential to cause adverse effects following prolonged use. This study, therefore, investigated the effects of combination treatment of a subliminal concentration of pioglitazone and quercetin, a potent antioxidant, on vascular reactivity of aorta isolated from fructose-streptozotocin (F-STZ)-induced diabetic rats. Relaxation to acetylcholine and sodium nitroprusside, and contraction to phenylephrine were tested in organ bath chambers following pre-incubation with vehicle (DMSO; 0...
February 16, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28195490/investigation-of-spatial-heterogeneity-of-salt-disproportionation-in-tablets-by-synchrotron-x-ray-diffractometry
#6
Sampada A Koranne, Ramprakash Govindarajan, Raj Suryanarayanan
Tablets which were binary mixtures of pioglitazone hydrochloride (PioHCl) with magnesium stearate (MgSt), croscarmellose sodium (CCS), microcrystalline cellulose or lactose monohydrate were prepared. Two sets of experiments, using intact tablets, were performed. (i) Tablets containing PioHCl (90% w/w) and MgSt were exposed to 25 or 40 °C and 75% RH in a custom built temperature/humidity chamber. In situ spatio-temporal mapping of disproportionation was performed by transmission mode synchrotron X-ray diffractometry (SXRD; Argonne National Labs)...
February 14, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28191533/inhibition-of-cyst-growth-in-pck-and-wpk-rat-models-of-polycystic-kidney-disease-with-low-doses-of-peroxisome-proliferator-activated-receptor-%C3%AE-agonists
#7
Stephanie M Flaig, Vincent H Gattone, Bonnie L Blazer-Yost
BACKGROUND AND OBJECTIVES: The studies were designed to test the efficacy of two peroxisome proliferator-activated receptor γ (PPARγ) agonists in two rodent models of polycystic kidney disease (PKD). MATERIALS AND METHODS: The PCK rat is a slowly progressing cystic model while the Wpk(-/-) rat is a rapidly progressing model. PCK rats were fed with a pharmacological (0.4 mg/kg body weight [BW]) and a sub-pharmacological (0.04 mg/kg BW) dose of rosiglitazone (week 4-28)...
September 1, 2016: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28186999/design-sythesis-and-evaluation-of-a-series-of-3-or-4-alkoxy-substituted-phenoxy-derivatives-as-ppars-agonists
#8
Jun Zhang, Xue-Jiao Wang, Xin Liu, Yi Huan, Miao-Miao Yang, Zhu-Fang Shen, Wen-Qing Jia, Zhi Jing, Shu-Qing Wang, Wei-Ren Xu, Xian-Chao Cheng, Run-Ling Wang
Peroxisome proliferators-activated receptors (PPARα, γ and δ) are potentially effective targets for Type 2 diabetes mellitus therapy. The severe effects of known glitazones and the successfully approved agents (saroglitazar and lobeglitazone) motivated us to study novelly potent PPARs drugs with improved safety profile. In this work, we received 15 carboxylic acids based on the combination principle to integrate the polar head of bezafibrate with the hydrophobic tail of pioglitazone. Another 12 tetrazoles based on the bioisosterism principle were obtained accordingly...
February 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28185715/effects-of-oral-antidiabetic-drugs-on-changes-in-the-liver-to-spleen-ratio-on-computed-tomography-and-inflammatory-biomarkers-in-patients-with-type-2-diabetes-and-nonalcoholic-fatty-liver-disease
#9
Koichi Yabiku, Akiko Mutoh, Kazufumi Miyagi, Nobuyuki Takasu
PURPOSE: Oral antidiabetic drugs (OADs) such as pioglitazone and metformin have beneficial effects in patients with nonalcoholic steatohepatitis. We prospectively assessed the effects of OADs on nonalcoholic fatty liver disease (NAFLD) in 886 men with type 2 diabetes mellitus and in a murine model of NAFLD. METHODS: Patients were randomized to receive pioglitazone, metformin, sitagliptin, or a non-OAD (control) for 6 months. All the patients received dietary and exercise guidance once a month during this study...
February 6, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28177092/-newer-anti-diabetic-therapies-and-chronic-kidney-disease
#10
Luca Di Lullo, Claudio Ronco, Vincenzo Barbera, Mario Cozzolino, Francesca Santoboni, Annalisa Villani, Antonio De Pascalis, Antonio Bellasi
Worldwide, an estimated 200 million people have chronic kidney disease (CKD), whose most common causes include hypertension, arteriosclerosis, and diabetes. About 40% of patients with diabetes develop CKD. Intensive blood glucose control through pharmacological intervention can delay CKD progression. Standard therapies for the treatment of type 2 diabetes include metformin, sulfonylureas, meglitinides, thiazolidinediones and insulin. While these drugs have an important role in the management of type 2 diabetes, only the thiazolidinedione pioglitazone can be used across the spectrum of CKD (stages 25) and without dose adjustment...
January 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28176623/effect-of-cinnamomum-cassia-on-the-pharmacokinetics-and-pharmacodynamics-of-pioglitazone
#11
Sandhya Mamindla, Prasad Koganti, Nagaraju Ravouru, Bharathi Koganti
: Back ground: Millions of people today use herbs either as food or in the form of medicine along with other medications. Many of the herbs can interact with these medications, causing either potentially dangerous side effects or improved or reduced benefits from the medication. OBJECTIVE: The present study was performed to determine the influence of cinnamon, on the pharmacokinetics and pharmacodynamics of pioglitazone. METHOD: Studies were conducted in normal and alloxan induced diabetic rats and rabbits with oral administration of selected doses of pioglitazone, cinnamon and their combination...
February 7, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28168204/rationale-design-and-baseline-characteristics-of-beijing-prediabetes-reversion-program-a-randomized-controlled-clinical-trial-to-evaluate-the-efficacy-of-lifestyle-intervention-and-or-pioglitazone-in-reversion-to-normal-glucose-tolerance-in-prediabetes
#12
Yingying Luo, Sanjoy K Paul, Xianghai Zhou, Cuiqing Chang, Wei Chen, Xiaohui Guo, Jinkui Yang, Linong Ji, Hongyuan Wang
Background. Patients with prediabetes are at high risk for diabetes and cardiovascular disease (CVD). No study has explored whether intervention could revert prediabetes to normal glycemic status as the primary outcome. Beijing Prediabetes Reversion Program (BPRP) would evaluate whether intensive lifestyle modification and/or pioglitazone could revert prediabetic state to normoglycemia and improve the risk factors of CVD as well. Methods. BPRP is a randomized, multicenter, 2 × 2 factorial design study. Participants diagnosed as prediabetes were randomized into four groups (conventional/intensive lifestyle intervention and 30 mg pioglitazone/placebo) with a three-year follow-up...
2017: Journal of Diabetes Research
https://www.readbyqxmd.com/read/28167117/protection-against-alcohol-induced-neuronal-and-cognitive-damage-by-the-ppar%C3%AE-receptor-agonist-pioglitazone
#13
Andrea Cippitelli, Esi Domi, Massimo Ubaldi, James C Douglas, Hong Wu Li, Gregory Demopulos, George Gaitanaris, Marisa Roberto, Paul D Drew, Cynthia J M Kane, Roberto Ciccocioppo
Binge alcohol drinking has emerged as a typical phenomenon in young people. This pattern of drinking, repeatedly leading to extremely high blood and brain alcohol levels and intoxication is associated with severe risks of neurodegeneration and cognitive damage. Mechanisms involved in excitotoxicity and neuroinflammation are pivotal elements in alcohol-induced neurotoxicity. Evidence has demonstrated that PPARγ receptor activation shows anti-inflammatory and neuroprotective properties. Here we examine whether treatment with the PPARγ agonist pioglitazone is beneficial in counteracting neurodegeneration, neuroinflammation and cognitive damage produced by binge alcohol intoxication...
February 3, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28166556/long-term-pioglitazone-treatment-for-patients-with-nonalcoholic-steatohepatitis
#14
Fernando Bril, Kenneth Cusi
No abstract text is available yet for this article.
February 7, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28166555/long-term-pioglitazone-treatment-for-patients-with-nonalcoholic-steatohepatitis
#15
James A Thomas, Rohit Gupta, Guruprasad P Aithal
No abstract text is available yet for this article.
February 7, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28166554/long-term-pioglitazone-treatment-for-patients-with-nonalcoholic-steatohepatitis
#16
Stuart K Sutton
No abstract text is available yet for this article.
February 7, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28154092/increased-peroxisome-proliferator-activated-receptor-gamma-activity-reduces-imatinib-uptake-and-efficacy-in-chronic-myeloid-leukemia-mononuclear-cells
#17
Jueqiong Wang, Liu Lu, Chung H Kok, Verity A Saunders, Jarrad M Goyne, Phuong Dang, Tamara M Leclercq, Timothy P Hughes, Deborah L White
Imatinib is actively transported by OCT-1 influx transporter, and low OCT-1 activity in diagnostic chronic myeloid leukemia blood mononuclear cells is significantly associated with poor molecular response to imatinib. Here we report that, in diagnostic chronic myeloid leukemia mononuclear cells and BCR-ABL1+ cell lines, peroxisome proliferator-activated receptor gamma agonists (GW1929, rosiglitazone, pioglitazone) significantly decrease OCT-1 activity; conversely, peroxisome proliferator-activated receptor gamma antagonists (GW9662, T0070907) increase OCT-1 activity...
February 2, 2017: Haematologica
https://www.readbyqxmd.com/read/28153916/effects-of-vitamin-d-combined-with-pioglitazone-hydrochloride-on-bone-mineral-density-and-bone-metabolism-in-type-2-diabetic-nephropathy
#18
Ling-Xu Wang, Na Wang, Qing-Li Xu, Wei Yan, Li Dong, Bao-Lin Li
The study aims to investigate the effect of vitamin D (VD) combined with pioglitazone hydrochloride (PIO) on bone mineral density (BMD) and bone metabolism in patients with type 2 diabetic nephropathy (T2DN). T2DN patients were selected and assigned into mild, moderate and severe groups. In each group, three therapy regimens (VD, PIO, and VD plus PIO) were administrated. X-ray absorptiometry was used to measure BMD. Intact parathyroid hormone (iPTH) and 25-OH-VD3 were measured by chemiluminescence meter. ELISA was applied to detect levels of osteoprotegerin (OPG), bone gla protein (BGP), C-terminal telopeptides of type I collagen (β-CTX), procollagen type I N propeptide (PINP), pyridinoline (Pyr), and deoxypyridinoline (D-Pyr)...
February 2, 2017: Bioscience Reports
https://www.readbyqxmd.com/read/28150448/ppar-%C3%AE-agonist-ameliorates-liver-pathology-accompanied-by-increasing-regulatory-b-and-t-cells-in-high-fat-diet-mice
#19
Zhipeng Xu, Gang Wang, Yuxiao Zhu, Ran Liu, Jingwei Song, Yangyue Ni, Hongzhi Sun, Bingya Yang, Min Hou, Lin Chen, Minjun Ji, Zan Fu
OBJECTIVE: Peroxisome proliferator-activated receptor (PPAR)-γ plays critical roles in human metabolic disorders. However, the mechanism remains incompletely understood. Regulatory cells contribute to these metabolic improvements; therefore, whether PPAR-γ agonist regulates regulatory cells was investigated. METHODS: C57BL/6J mice received a normal or high-fat diet (HFD) with or without pioglitazone treatment. Mice were sacrificed for detecting the metabolic parameters...
February 2, 2017: Obesity
https://www.readbyqxmd.com/read/28143858/phenotyping-of-adipose-liver-and-skeletal-muscle-insulin-resistance-and-response-to-pioglitazone-in-spontaneously-obese-rhesus-monkeys
#20
Jin Shang, Stephen F Previs, Stacey Conarello, Keefe Chng, Yonghua Zhu, Sandra C Souza, Michael Staup, Ying Chen, Dan Xie, Emanuel Zycband, Karni Schlessinger, Victoria Plamadeala Johnson, Gladys Arreaza, Franklin Liu, Diane Levitan, Liangsu Wang, Margaret van Heek, Mark Erion, Yixin Wang, David E Kelley
Insulin resistance and diabetes can develop spontaneously with obesity and aging in rhesus monkeys, highly similar to the natural history of obesity, insulin resistance and progression to type 2 diabetes in humans. The current studies in obese rhesus were undertaken to assess hepatic and adipose contributions to systemic insulin resistance, currently a gap in our knowledge, and to benchmark the responses to pioglitazone (PIO). A 2-step hyperinsulinemic-euglycemic clamp, with tracer-based glucose flux estimates, was used to measure insulin resistance and in an intervention study was repeated following six weeks of PIO treatment (3 mg/kg)...
January 31, 2017: American Journal of Physiology. Endocrinology and Metabolism
keyword
keyword
84235
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"